The BREAKWATER trial showed improved response rates and survival with Braftovi, Erbitux, and chemotherapy in BRAF V600E-mutated metastatic colorectal cancer. FDA approval in December 2024 highlights ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer. In December 2024, the United States Food and Drug ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

SM Prime said that SMXCITE, together with SMX Manila, will offer over 35,000 square meters of combined space, further reinforcing the MOA Complex’s appeal as a destination for international ...

In the Philippines, few developments reflect this shift more clearly than the Mall of Asia (MOA) complex in Pasay City. Across a single district, MOA brings together a rare convergence ...

Food and feed manufacture new product development time and cost can be significantly cut using a new AI-driven microbiology platform launched by MOA Food. The European biotech start-up claims its ...

Between 2020 and 2024, 53 combination therapies applied for expanded reimbursement, but only one cross-company case (Braftovi and Erbitux for colorectal cancer) was approved, according to data ...

Held at the SM Mall of Asia Arena, the Autism Society Philippines’ Angels Walk 2025 brought together over 40,000 advocates in a nationwide movement for autism appreciation, accommodation, and ...

MoA All America Fund earns an Average Process Pillar rating. The most meaningful contributor to the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm ...

Two-drug therapy with Braftovi and Erbitux also performed well, with an OS of 8.4 months. Kopetz tweeted that the response rates in second-line patients was 34% for the triplet, 22% for the ...

New research reinforcing the role of ERBITUX ® (cetuximab) in colorectal cancer (Abstracts 3513, LBA3500) Investigator-sponsored research continues to reinforce ERBITUX as the backbone of ...